GSK’s Blenrep returns to the US market after FDA approves resubmission

GSK's Blenrep returns to the US market after FDA approves resubmission

The FDA has approved GSK's Blenrep in combination with bortezomib and dexamethasone, clearing the drug's return to the US market. The move ends a withdrawal that followed a failed confirmatory study and resets the catalyst timeline for investors and BD teams.

IntelligenceRegulatory Impact▾

FDA decisions frame this story. Regulatory relevance is high for blood cancer, with Blenrep and belantamab mafodotin-blmf most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Blenrep (belantamab mafodotin-blmf) is now approved in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy.
• Blenrep was initially withdrawn from the US market in 2022 after failing a confirmatory clinical trial, and the FDA approval now enables a return to the US market.
• Blenrep remains available only through the BLENREP Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of eye problems.
• Multiple recruiting and active trials are underway, including NCT07227311 and NCT05847569, tracking belantamab mafodotin combinations in relapsed-refractory and triple-class refractory settings.

IntelligenceCompetitive Intelligence▾

GSK are directly implicated. Competitive pressure reads medium — compare pipeline positioning and partnership scouting against signals in this story.

FDA approval resets Blenrep's US market status

GSK's Blenrep (belantamab mafodotin-blmf) is now indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy. This approval marks a formal return to the US market after a period of withdrawal.

IntelligenceMarket Signals▾

Commercial pull is high and investment relevance high for blood cancer. Expect implications for pricing, access, and launch sequencing.

Why Blenrep's withdrawal matters for this approval

Blenrep was initially withdrawn from the US market in 2022 after failing a confirmatory clinical trial. The regulatory reset matters for investors and BD teams because the drug was previously pulled from the market, and this approval reopens the commercial pathway.

IntelligenceStrategic Takeaways▾

Blenrep (belantamab mafodotin-blmf) is now approved in combination with bortezomib and dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy . Blenrep was initially withdrawn from the US market in 2022 after failing a confirmatory clinical trial , and the FDA approval now enables a return to the US market. Blenrep remains available only thr

REMS restricts access despite FDA approval

Blenrep is available in the US only through the BLENREP Risk Evaluation and Mitigation Strategy (REMS) program due to the risk of eye problems. This restricted distribution model creates practical access constraints for prescribers and patients even with FDA approval in place.

IntelligenceEvidence Quality▾

Grounded in 1 regulatory source and 1 peer-reviewed source.

Clinical evidence from DREAMM-7 supports the combination

In the DREAMM-7 clinical study, patients taking the combination of Blenrep, bortezomib, and dexamethasone stayed in remission for a median of 31 months. Belantamab mafodotin has demonstrated a long-lasting effect in heavily pretreated multiple myeloma patients, according to published literature.

Ongoing trials define the next catalyst window

Multiple belantamab mafodotin studies are active or recruiting. NCT07227311, a Phase 2 study, is currently recruiting participants to evaluate the efficacy and safety of belantamab mafodotin in combination with standard of care in relapsed-refractory multiple myeloma. NCT05847569, a Phase 2 trial sponsored by Mayo Clinic, is recruiting to evaluate alternate doses and dosing schedules of belantamab mafodotin for treatment of triple-class refractory multiple myeloma.

NCT07285239, a Phase 3 trial not yet recruiting, will evaluate belantamab mafodotin or daratumumab with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma. NCT04876248, a Phase 2 trial at Roswell Park Cancer Institute, is active and not recruiting, studying belantamab mafodotin and lenalidomide for multiple myeloma patients with minimal residual disease positive after stem cell transplant.

Frequently Asked Questions

Related profiles

• BLENREP
• bortezomib
• dexamethasone

Related coverage

• EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
• Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win
• EMA backs datopotamab deruxtecan for advanced lung cancer